Eugia Pharma Specialities Limited, a wholly owned subsidiary of Aurobindo Pharma Limited, has announced the launch of Pomalidomide Capsules in the US market.
The capsules are available in strengths of 1 mg, 2 mg, 3 mg and 4 mg and are the generic equivalent of Pomalyst capsules marketed by Bristol Myers Squibb. Eugia Pharma was among the first-to-file (FTF) applicants for the Abbreviated New Drug Application (ANDA) for this product. The capsules will be manufactured at Eugia Unit-I.
According to IQVIA MAT data for the 12 months ending January 2026, the Pomalidomide Capsules market in the US is estimated to be around $3.3 billion.
Pomalidomide is a third-generation immunomodulatory drug used in combination with dexamethasone, and sometimes bortezomib, for the treatment of relapsed or refractory Multiple Myeloma and AIDS-related Kaposi Sarcoma.